创伤患者精神活性药物使用的长期结局:多中心患者报告结局研究
本研究为多中心患者报告结局研究,纳入3家一级创伤中心中损伤严重度评分>9且入院时有毒理学筛查的创伤患者,伤后6-12个月电话随访。571例纳入分析,30.3%入院时精神活性药物筛查阳性。调整基线特征后,精神活性药物使用与每日慢性疼痛、精神障碍和社会功能障碍独立相关,但功能受限无差异。提示创伤住院是识别高危患者并干预的窗口。
要点
- 创伤患者入院毒理学筛查精神活性药物阳性率30.3%(173/571),中位年龄43岁,穿透伤比例更高(8.7% vs 4.3%)。
- 调整基线精神共病等特征后,精神活性药物使用与伤后6-12个月每日慢性疼痛、精神障碍独立相关。
- 精神活性药物使用与社会功能障碍独立相关(SF-36 v2社会功能子域≤47分定义社会功能障碍)。
- 精神活性药物使用与功能受限无差异,提示长期负担主要集中在疼痛、心理和社会功能层面。
- 创伤住院可作为识别精神活性药物使用高危患者并减轻其长期影响的时机。
适用人群与场景
- 3家一级创伤中心收治的中重度创伤患者(损伤严重度评分>9),入院时完成毒理学筛查,伤后6-12个月可电话随访者。
诊断标准与关键阈值
- 精神活性药物使用定义为入院毒理学筛查检出非处方精神活性物质,包括安非他明、巴比妥类、苯二氮䓬类、大麻素、甲基安非他明、美沙酮、阿片类、羟考酮、亚甲二氧基甲基安非他明(摇头丸)、苯环己哌啶、三环类抗抑郁药和可卡因。
- 社会功能障碍定义为健康调查简表第2版社会功能子域评分≤47分。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:多中心患者报告结局研究(前瞻性电话随访),3家一级创伤中心,纳入571例(占1699例合格者的34%),173例(30.3%)入院毒理学筛查精神活性药物阳性。
- 精神活性药物阳性组更年轻(中位43[28-55]岁 vs 66[46-78]岁,p<0.001),穿透伤更多(8.7% vs 4.3%,p=0.036),大学教育比例更低(41.3% vs 54.5%,p=0.004)。
- 调整患者特征包括基线精神共病后,精神活性药物阳性与伤后6-12个月每日慢性疼痛、精神障碍、社会功能障碍独立相关;功能受限两组无差异。
证据类型、等级与局限
- 证据类型:多中心观察性研究(预后/流行病学),证据等级level III。
- 局限:仅34%合格患者纳入分析,可能存在选择偏倚;观察性设计不能确立因果关系;原文未提及失访情况。
对床旁实践的改变
- 对中重度创伤患者(ISS>9)入院时毒理学筛查精神活性药物阳性者,应在伤后6-12个月关注每日慢性疼痛、精神障碍和社会功能障碍,而非仅关注功能受限。
- 创伤住院期间可识别精神活性药物使用高危患者,但原文未提供具体干预措施。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Psychoactive drug use (PDU) is reported in up to 40% of trauma patients and is associated with a higher rate of in-hospital complications. However, little is known about its long-term impact on trauma patients. We aimed to assess the long-term functional, mental, and psychosocial outcomes of PDU in trauma patients 6 to 12 months after injury.
METHODS: Trauma patients with moderate to severe injuries (Injury Severity Score, >9) who had a toxicology screen upon admission to one of three level 1 trauma centers were contacted by phone 6 to 12 months postinjury. Psychoactive drug use was defined as the presence of a psychoactive, nonprescribed substance on toxicology screen including amphetamine, barbiturate, benzodiazepine, cannabinoid, methamphetamine, methadone, opioid, oxycodone, methylenedioxymethamphetamine (ecstasy), phencyclidine, tricyclic antidepressant, and cocaine. The interviews systematically evaluated functional limitations, social functioning, chronic pain, and mental health (posttraumatic stress disorder, depression, anxiety). Patients with a score of ≤47 on the Short-Form Health Survey version 2.0 social functioning subdomain were considered to have social dysfunction. Multivariable regression models were built to determine the independent association between PDU and long-term outcomes.
RESULTS: Of the 1,699 eligible patients, 571 (34%) were included in the analysis, and 173 (30.3%) screened positive for PDU on admission. Patients with PDU were younger (median age [interquartile range], 43 [28-55] years vs. 66 [46-78] years, p < 0.001), had more penetrating injuries (8.7% vs. 4.3%, p = 0.036), and were less likely to have received a college education (41.3% vs. 54.5%, p = 0.004). After adjusting for patients' characteristics including the presence of a baseline psychiatric comorbidity, patients with PDU on admission were more likely to suffer from daily chronic pain, mental health disorders, and social dysfunction 6 to 12 months after injury. There was no difference in the functional limitations between patients with and without PDU.
CONCLUSION: On the long term, PDU in trauma patients is strongly and independently associated with worse mental health, more chronic pain, and severe impairment in social functioning. A trauma hospitalization presents an opportunity to identify patients at risk and to mitigate the long-term impact of PDU on recovery.
LEVEL OF EVIDENCE: Prognostic/epidemiologic, level III.
参考来源
- El Moheb M, Herrera-Escobar JP, Breen K, et al. Long-term outcomes of psychoactive drug use in trauma patients: A multicenter patient-reported outcomes study. J Trauma Acute Care Surg. 2021. PMID: 33264267. doi:10.1097/TA.0000000000003032
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。